These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34693520)

  • 1. Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3.
    Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Herbst F; Peyrard S; Pelov D; French JA
    Epilepsia; 2021 Dec; 62(12):3029-3041. PubMed ID: 34693520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.
    Curatolo P; Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; de Vries PJ; Dlugos DJ; Fan J; Ridolfi A; Pelov D; Voi M; French JA
    Lancet Child Adolesc Health; 2018 Jul; 2(7):495-504. PubMed ID: 30169322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan.
    Mizuguchi M; Ikeda H; Kagitani-Shimono K; Yoshinaga H; Suzuki Y; Aoki M; Endo M; Yonemura M; Kubota M
    Brain Dev; 2019 Jan; 41(1):1-10. PubMed ID: 30060984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
    French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Berkowitz N; Voi M; Peyrard S; Pelov D; Franz DN
    Lancet; 2016 Oct; 388(10056):2153-2163. PubMed ID: 27613521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
    Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of epilepsy with everolimus in tuberous sclerosis.
    Krueger DA; Wilfong AA; Mays M; Talley CM; Agricola K; Tudor C; Capal J; Holland-Bouley K; Franz DN
    Neurology; 2016 Dec; 87(23):2408-2415. PubMed ID: 27815402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
    Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
    Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
    Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
    Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial.
    Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Voi M; Fan J; Vaury A; Pelov D; French JA
    Neurol Clin Pract; 2018 Oct; 8(5):412-420. PubMed ID: 30564495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
    Krueger DA; Wilfong AA; Holland-Bouley K; Anderson AE; Agricola K; Tudor C; Mays M; Lopez CM; Kim MO; Franz DN
    Ann Neurol; 2013 Nov; 74(5):679-87. PubMed ID: 23798472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study.
    Stockinger J; Strzelczyk A; Nemecek A; Cicanic M; Bösebeck F; Brandt C; Hamer H; Intravooth T; Steinhoff BJ
    Epilepsia; 2021 Mar; 62(3):785-794. PubMed ID: 33534134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies.
    Wiegand G; May TW; Lehmann I; Stephani U; Kadish NE
    Seizure; 2021 Dec; 93():111-119. PubMed ID: 34740140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
    Okanishi T; Fujimoto A; Nishimura M; Baba S; Itamura S; Okanari K; Enoki H
    Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
    BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
    N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
    Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.